Posters

POSTER SUBMISSION GUIDELINES

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer reviewed. Submission is free.

SUBMIT YOUR ABSTRACT

Enter the following information to this Submission Form:

  • Poster Title
  • Your Name
  • Your Institution
  • Your Email
  • Abstract describing the poster

All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

Questions? Email Posters@LabRoots.com

LabRoots Policy

OCT 10 - 11 2018 Opens: 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Cancer Research & Oncology 2018

The 6th Annual Cancer Research & Oncology Virtual Event will take place October 10-11, 2018. The free, two-day online event will bring research professionals, scientists, and clinicians from around the world to learn and discuss recent advances in cancer research. As with all LabRoots event, the Cancer Research and Oncology Event encourages a worldwide collaboration and connections between colleagues and field experts.

Cancer research has made major advancements in diagnosis, treatments, and the basic understanding of the disease itself. Each year we see progress in immunotherapy, treatments involving nanotechnology, advances in targeted and personalized therapeutics and drug development, and a decrease in mortality rates due to a strong focus on learning more about the origination of the disease.

Cancer Research & Oncology 2018 will address a range of topics, such as:

  • Cancer vaccines
  • Immunotherapy and other therapeutics
  • Analysis of tumor growth
  • Immunogenic cell death in cancer: the quantity/quality conundrum”
  • Biomarker discovery from big pharmacogenomic data
  • Cancer epigenetics
    • Genetic markers / Biomarkers
  • Organ-specific cancers
    • ENT / Thyroid
    • Breast
    • Colon
    • Lung
    • Multiple Myelomas
    • Neuro-oncology

Our virtual conference allows you to participate in a global setting with no travel or cost to you. You can participate in exactly those parts which you are interested in and be back at your desk or bench in an instant. Virtual events remove time and place restrictions and ensure that everyone who wants to participate can do so. This virtual conference also offers increased reach for the global cancer community with a high degree of interaction through live-streaming video and chat sessions.


Call for Speakers —  We are always looking to feature excellent research during our virtual events. If you’re working on some remarkable breakthroughs and would like to submit a speaker or panel for consideration, please submit your abstract here.

Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2018 Cancer Research and Oncology Virtual Event. Submission is free. Submit your abstract here

Continuing Education
By participating in this virtual event and watching webcast presentations, you can earn Free Continuing Education (PACE). To earn educational credits, you must view an entire presentation. Following the presentation, you must click on the educational credit link provided for that particular speaker and follow the required process. Once you have completed the process, you will receive a certificate for the educational credit.

Use #LRcancer to follow the conversation!


Speakers
  • Director and Professor, Biological Sciences Division, Pacific Northwest National Laboratory
  • Program Director, National Science Foundation
  • Post-Doctoral Fellow, Princess Margaret Cancer Research, University Health Network
  • Senior Scientist and Neurosurgeon, Garron Family Chair in Childhood Cancer Research, The Hospital for Sick Children, Professor of Surgery and Molecular Genetics, University of Toronto
  • Assistant Professor, Weill Cornell Medical College/New York Presbyterian
  • Research Director, French Institute of Health and Medical Research
  • Assistant Professor, Princess Margaret Cancer Center, University of Toronto
  • Professor of Immunology, Mayo Clinic
  • Assistant Professor, Department of Molecular and Integrative Physiology, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Rogel Cancer Center, University of Mich
  • Senior Research Associate, Cancer Genome Evolution Research Group, University College London
  • Senior Field Application Scientist, Bioinformatics, QIAGEN
  • Associate Director, NGS Assay Technologies, QIAGEN
  • Post Doctoral Research Scholar at University of California, San Francisco
  • Professor of Pediatrics, Department of Human Oncology & Genetics, University of Wisconsin-Madison
  • Associate Consultant, Department of Surgery & Department of Obstetrics & Gynecology, Assistant Professor, Microbiome Program, Center for Individualized Medicine, Mayo Clinic
  • Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center
  • Associate Professor, Biomanufacturing Research Institute and Technology Enterprise, NC Central University
  • Medical Director, Head and Neck Oncology, Massachusetts General Hospital

Show Resources
Agenda
  • OCT 10, 2018 06:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    The Role of Vaccination for the Treatment and Prevention of Breast and Ovarian Cancers
    Speaker: Keith Knutson, PhD
  • OCT 10, 2018 07:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: Proteogenomics and Cancer Biology: Insights for Prognosis and Therapy
    Speaker: Karin Rodland, PhD
  • OCT 10, 2018 09:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Using Radiotherapy, Tumor-Reactive mAb and IL2 to Engage Innate and Adaptive Antitumor Immunity
    Speaker: Paul Sondel, MD, PhD
  • OCT 10, 2018 10:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Metabolic Networks in the Tumor Microenvironment
    Speaker: Costas A. Lyssiotis, PhD
    Sponsored By: Agilent
  • OCT 10, 2018 10:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Understanding Response to Cancer Therapy Via Translational Research
  • OCT 10, 2018 12:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Discovery of Biomarkers Predictive of Anticancer Drug Response in Preclinical Settings
    Speaker: Benjamin Haibe-Kains, PhD
  • OCT 10, 2018 12:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Integrative Cancer Immunology and Novel Concepts of Cancer Evolution
    Speaker: Jerome Galon, PhD
  • OCT 10, 2018 12:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Sample to Insight: Everything You Need to Know About RNA Sequencing
    Speaker: Jonathan Shaffer, PhD
    Sponsored By: QIAGEN
  • OCT 10, 2018 01:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Immunogenic Cell Death in Cancer: The Quantity/Quality Conundrum
    Speaker: Lorenzo Galluzzi, PhD
  • OCT 11, 2018 06:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Homing in on RET; New Precision Medicine Approaches in RET-Driven Cancers
  • OCT 11, 2018 09:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Destabilization and Degradation of MYC: More Ways Than One
    Speaker: Jason De Melo, PhD
  • OCT 11, 2018 09:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Discovering Cellular Mechanisms and Markers in Anti-PD1 Non-Responders Through Ingenuity Pathway Analysis and Oncoland
    Speaker: Devendra Mistry, PhD
    Sponsored By: QIAGEN
  • OCT 11, 2018 01:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Aurora Kinase A Drives The Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer
    Speaker: Khyati Shah, PhD
  • Cancer Therapeutics and Vaccines
  • OCT 10, 2018 06:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    The Role of Vaccination for the Treatment and Prevention of Breast and Ovarian Cancers
    Speaker: Keith Knutson, PhD
  • OCT 10, 2018 09:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Using Radiotherapy, Tumor-Reactive mAb and IL2 to Engage Innate and Adaptive Antitumor Immunity
    Speaker: Paul Sondel, MD, PhD
  • OCT 10, 2018 10:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Understanding Response to Cancer Therapy Via Translational Research
  • OCT 10, 2018 12:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Integrative Cancer Immunology and Novel Concepts of Cancer Evolution
    Speaker: Jerome Galon, PhD
  • OCT 11, 2018 06:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Homing in on RET; New Precision Medicine Approaches in RET-Driven Cancers
  • OCT 11, 2018 01:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Aurora Kinase A Drives The Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer
    Speaker: Khyati Shah, PhD
  • OCT 10, 2018 07:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: Proteogenomics and Cancer Biology: Insights for Prognosis and Therapy
    Speaker: Karin Rodland, PhD
  • OCT 10, 2018 10:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Metabolic Networks in the Tumor Microenvironment
    Speaker: Costas A. Lyssiotis, PhD
    Sponsored By: Agilent
  • OCT 10, 2018 12:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Sample to Insight: Everything You Need to Know About RNA Sequencing
    Speaker: Jonathan Shaffer, PhD
    Sponsored By: QIAGEN
  • OCT 10, 2018 01:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Immunogenic Cell Death in Cancer: The Quantity/Quality Conundrum
    Speaker: Lorenzo Galluzzi, PhD
  • OCT 11, 2018 09:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Discovering Cellular Mechanisms and Markers in Anti-PD1 Non-Responders Through Ingenuity Pathway Analysis and Oncoland
    Speaker: Devendra Mistry, PhD
    Sponsored By: QIAGEN
  • Cancer Diagnostics
  • OCT 10, 2018 12:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Discovery of Biomarkers Predictive of Anticancer Drug Response in Preclinical Settings
    Speaker: Benjamin Haibe-Kains, PhD
  • Cancer Epigenetics and Natural History
  • OCT 11, 2018 09:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Destabilization and Degradation of MYC: More Ways Than One
    Speaker: Jason De Melo, PhD
Speakers

We are always looking to feature excellent research during our virtual events. If you’re working on some remarkable breakthroughs and would like to submit a speaker or panel for consideration, please submit your abstract here.


  • Karin Rodland, PhD
    Director and Professor, Biological Sciences Division, Pacific Northwest National Laboratory
    Biography
      Dr. Karin Rodland joined the Biological Sciences Division at the Pacific Northwest National Laboratory in October 2001, after serving seventeen years on the faculty of Oregon Health Sciences University. As Chief Scientist for Biomedical Research at PNNL, she has promoted the application of PNNL's traditional strengths in mass spectrometry, proteomics, and systems biology to important problems in biomedical research. She is currently the PNNL co-Director of the OHSU-PNNL Precision Medicine Innovation CoLaboratory, a joint effort dedicated to improving patient outcomes through the integration of cutting edge technologies in integrated omics, imaging, and data analysis to advance the goals of precision medicine. Dr. Rodland's own research focuses on signal transduction pathways that regulate proliferation in normal and malignant cells. She was the first to recognize the role of the calcium-sensing receptor in modulating proliferation in response to small molecules in the extracellular environment. Since joining PNNL, she has adopted a systems biology approach to signal transduction and has become a recognized expert in the field of proteomics and cancer biomarkers. She is a full member of the National Cancer Institute's Early Detection Research Network, and is the chair of the Clinical Proteomics Tumor Analysis Consortium Steering Committee. She has served as Chair of the Cancer Biomarkers Study Section for the NIH, as well as the Department of Defense Congressionally Directed Medical Research Program Integration Panels for both Ovarian and Breast Cancer Research.
    • Krastan Blagoev
      Program Director, National Science Foundation
    • Jason De Melo, PhD
      Post-Doctoral Fellow, Princess Margaret Cancer Research, University Health Network
    • Peter Dirks, MD, PhD
      Senior Scientist and Neurosurgeon, Garron Family Chair in Childhood Cancer Research, The Hospital for Sick Children, Professor of Surgery and Molecular Genetics, University of Toronto
      Biography
        Dr. Peter Dirks graduated from Queen's University Medical School in Kingston, Ontario in 1989. Then, he completed his PhD in Molecular and Cellular Pathology in 1997 at the University of Toronto, his neurosurgery training at the University of Toronto in 1998 (Fellow of the Royal College of Surgeons, Canada, 1998) and his Paediatric Neurosurgery Fellowship training at L'hôpital Necker Enfants Malades (Paris) in 1998. Dirks was appointed to Neurosurgical Staff at The Hospital for Sick Children (SickKids) and the University of Toronto in 1998 and appointed to the SickKids Research Institute's Developmental & Stem Cell Biology Program in 1999. He established his research laboratory to study brain tumours in the Arthur and Sonia Labatt Brain Tumour Research Centre at SickKids in 1999.
      • Lorenzo Galluzzi, PhD
        Assistant Professor, Weill Cornell Medical College/New York Presbyterian
        Biography
          Lorenzo Galluzzi (born 1980) is currently Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College (New York, USA), and Honorary Associate Professor at the Faculty of Medicine of the Paris Descartes University (Paris, France). Prior to joining Weill Cornell Medical College (2017), Lorenzo Galluzzi was a Junior Scientist of the Research Team "Apoptosis, Cancer and Immunity" at the Cordeliers Research Center (Paris, France; 2012-2016). Lorenzo Galluzzi did his post-doctoral training at the Gustave Roussy Cancer Center (Villejuif, France; 2009-2011), after receiving his PhD from the Paris Sud University (Le Kremlin-Bicetre, France; 2005-2008). He is also Associate Director of the European Academy for Tumor Immunology (EATI), and Founding Member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP). Lorenzo Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. In particular, he provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeting immune response in the context of chemotherapy and radiation therapy. Lorenzo Galluzzi has published more than 350 scientific articles in international peer-reviewed journals. According to a survey published by Lab Times, he is currently the 6th and the youngest of the 30 most-cited European cell biologists (relative to the period 2007-2013). Lorenzo Galluzzi currently operates as Editor-in-Chief of three journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, and Molecular and Cellular Oncology (which he co-founded in 2013). In addition, Lorenzo Galluzzi currently serves as Section Chief Editor for Oncotarget (Autophagy and Cell Death section), Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease.
        • Jerome Galon, PhD
          Research Director, French Institute of Health and Medical Research
          Biography
            Dr. Jérôme Galon specialized in the fields of immunology and cancer, Jérôme Galon is Research Director at INSERM (French NIH), and head of the laboratory of Integrative Cancer Immunology, in Paris, France. He is associate Director and co-founder of European Academy of Tumor Immunology (EATI), board member of Society for Immunotherapy of Cancer (SITC). His work on the comprehensive analysis of the tumor-microenvironment and the role of T-cells in human cancer led to the demonstration of the importance of adaptive pre-existing immunity in human cancer, and the concept of cancer immune-contexture. He pioneered the Immunoscore. He is the co-founder of HalioDx company and the Chairman of its scientific council. His contributions have been recognized with numerous awards, including the William B. Coley Award, an international prize which honors the best scientists in the fundamental and cancer immunology, and Award from the National Academy of Science, and Award from the National Academy of Medicine.
          • Benjamin Haibe-Kains, PhD
            Assistant Professor, Princess Margaret Cancer Center, University of Toronto
            Biography
              Benjamin Haibe-Kains is a Scientist at the Princess Margaret Cancer Centre (PM), University Health Network, and Assistant Professor in the Medical Biophysics and Computer Science departments of the University of Toronto. Dr. Haibe-Kains earned his PhD in Bioinformatics at the Université Libre de Bruxelles (Belgium), for which he was awarded a Solvay Award (Belgium). Supported by a Fulbright Award, Dr. Haibe-Kains did his postdoctoral fellowship at the Dana-farber Cancer Institute and Harvard School of Public Health (USA). Dr. Haibe-Kains started his own laboratory at the Institut de Recherches Cliniques de Montréal (Canada) and moved to PM in November 2013. Dr. Haibe-Kains' research focuses on the integration of high-throughput data from various sources to simultaneously analyze multiple facets of carcinogenesis. Dr. Haibe-Kains and his team are analyzing high-throughput (pharmaco)genomic datasets to develop new prognostic and predictive models and to discover new therapeutic regimens in order to significantly improve disease management. Dr. Haibe-Kains' main scientific contributions include several prognostic gene signatures in breast cancer, subtype classification models for ovarian and breast cancers, as well as genomic predictors of drug response in cancer cell lines.
            • Keith Knutson, PhD
              Professor of Immunology, Mayo Clinic
              Biography
                Keith L. Knutson, Ph.D., is a consultant in the Department of Immunology, Mayo Clinic in Florida, where he also serves as director of the Discovery and Translation Lab's Cancer Research Program. Dr. Knutson joined the staff of Mayo Clinic in 2005 and holds the academic rank of Professor of Immunology, Mayo Clinic College of Medicine and Science. Dr. Knutson is also Director of the Mayo Clinic Cancer Center's Cancer Immunology and Immunotherapy Program. Dr. Knutson received his B.S. in Microbiology at the University of Washington. He earned his Ph.D. in Physiology and Pharmacology from the University of Georgia and completed two postdoctoral fellowships in immunology, one at the University of British Columbia and the other at the University of Washington. Dr. Knutson is internationally recognized in the field of cancer immunology. His research focuses on the immunology and immunotherapy of breast and ovarian cancers, both the basic immunobiology and clinical translation, including clinical trials. His contributions to science include clinical development and testing of self-tumor antigen-specific vaccines in patients with breast and ovarian cancers. He currently has three FDA-approved vaccine trials underway and is principal investigator of 3 Department of Defense grants to test vaccines aimed at preventing recurrence breast cancer, including triple negative breast cancer for which there are no targeted therapies. Dr. Knutson is frequently invited to give presentations on his research both domestically and internationally, and he has authored numerous journal articles, abstracts and other written publications, consistently publishing in high-impact scientific journals. Additionally, he holds reviewer responsibilities for several prominent publications. In recognition of his work, Dr. Knutson has received many awards and honors, including the Young Investigator Award-Pharmingen, conferred by the American Association for Cancer Research, and the prestigious Howard Temin Award, conferred by the National Institutes of Health, National Cancer Institute. He is also recognized as the 2017 Investigator of the Year at the Mayo Clinic campus in Florida. In addition to his research activities, Dr. Knutson is active in education and has mentored postdoctoral fellows, research associates and medical students, among others. He holds full faculty privileges in Immunology in Mayo Clinic Graduate School of Biomedical Sciences. Dr. Knutson's has several current and past memberships with professional organizations which include the Breast Cancer Research Program and the Ovarian Cancer Research Program of the United States Department of Defense, the Tumor Microenvironment Study Section of the U.S. National Institutes of Health Center for Scientific Review, and the Education and Training Committee for the Society for the Immunotherapy of Cancer. He is a Principal Investigator of the Artemis Project, National Breast Cancer Coalition, where he is leading efforts to produce prevention vaccines for breast cancer.
              • Costas A. Lyssiotis, PhD
                Assistant Professor, Department of Molecular and Integrative Physiology, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Rogel Cancer Center, University of Mich
                Biography
                  Costas A. Lyssiotis obtained his bachelor's degree in Chemistry and Biochemistry from the University of Michigan in 2004, his PhD in Chemical Biology from The Scripps Research Institute in 2010, and then completed postdoctoral training in the laboratory of Lewis C. Cantley at Harvard and Cornell. In 2015, Dr. Lyssiotis joined the faculty at the University of Michigan with appointments in the Departments of Physiology and Medicine. His lab studies the biochemical pathways and metabolic requirements that enable tumor survival and growth. This work spans the areas of cancer metabolism, the tumor microenvironment and immunometabolism using and developing protocols in mass spectrometry-based metabolomics. Ultimately, his group aims to transition new information about these processes into targeted therapies for cancer and other diseases. He is the recipient of several junior scholar awards including being named a Lefkofsky Scholar, a Kimmel Scholar, an AACR NextGen young investigator, a Dale F. Frey Breakthrough Scientist, and a V Foundation Fellow.
                • Nicholas McGranahan, PhD
                  Senior Research Associate, Cancer Genome Evolution Research Group, University College London
                • Devendra Mistry, PhD
                  Senior Field Application Scientist, Bioinformatics, QIAGEN
                  Biography
                    Devendra (Dev) received his PhD from University of California San Diego(UCSD) Biomedical Sciences graduate program and did postdoctoral studies under both academic and pharmaceutical settings. During his post-doctoral studies, he focused on cellular mechanisms regulating stem cells and cancer stem cells through next-gen sequencing data generation, analysis, interpretation and mining. Dev joined QIAGEN as a field application scientist in 2015. In the past 3 years, he has provided trainings to many pharma, biotech, academic and government investigators for different QIAGEN bioinformatics software. In addition, he has helped many of these users troubleshoot problems with their existing workflows and design new workflows.
                  • Jonathan Shaffer, PhD
                    Associate Director, NGS Assay Technologies, QIAGEN
                    Biography
                      Dr. Shaffer joined QIAGEN in 2009 and has since worked with various technology development groups, the most recent being miRNA technologies. He received his Ph.D. in biochemistry and molecular genetics from the University of Pittsburgh School of Medicine in 2008 where his research focused on determining the mechanisms that regulate non-receptor tyrosine kinase expression and activity. Dr. Shaffer did his postdoctoral training at SABiosciences Corporation, now part of QIAGEN. Currently, Dr. Shaffer is a Senior Scientist in product development at QIAGEN .
                    • Khyati Shah, PhD
                      Post Doctoral Research Scholar at University of California, San Francisco
                      Biography
                        Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in breast cancer. Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.
                      • Paul Sondel, MD, PhD
                        Professor of Pediatrics, Department of Human Oncology & Genetics, University of Wisconsin-Madison
                      • Marina Walther-Antonio, PhD
                        Associate Consultant, Department of Surgery & Department of Obstetrics & Gynecology, Assistant Professor, Microbiome Program, Center for Individualized Medicine, Mayo Clinic
                        Biography
                          Marina Walther-Antonio, PhD is an Associate Consultant in the Department of Surgery and Department of Obstetrics and Gynecology and an Assistant Professor in the Microbiome Program at Mayo Clinic. She leads an interdisciplinary research program that studies the role of the human microbiome in women's health, and in gynecologic cancers in particular. In order to achieve this, Dr. Walther-Antonio and her research team have characterized the female reproductive tract microbiome in benign gynecologic conditions, cancer precursors, and endometrial and ovarian cancer manifestation. Their efforts have resulted in the identification of microbiota markers for endometrial cancer and in the development of translational approaches towards early detection and prevention of the disease. The ultimate goal is to pinpoint intervention opportunities that are amenable to modification of disease risk or can diminish the use of aggressive therapeutic options. Dr. Walther-Antonio's ovarian cancer research is concentrated on the search for an early detection microbiome biomarker and mechanistic role in response to therapy involving monitoring during a clinical trial and patient derived xenograft mouse model. Because mechanistic microbiome studies benefit from complex host/microbe interrogation with a cellular level of resolution, the research team is also focused on the development and application of single-cell microfluidic technologies, such as Optofluidics and Digital Microfluidics.
                        • Jennifer Wargo, MD
                          Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center
                          Biography
                            Dr. Wargo's career commitment is to advance the understanding and treatment of disease through science. After completing her medical degree, she entered surgical residency training at the Massachusetts General Hospital/Harvard Medical School where... she became interested in the biology and treatment of cancer. During her training, she completed 2 fellowships in surgical oncology with a focus on immunotherapy for cancer. Dr. Wargo was recruited to the Division of Surgical Oncology at Massachusetts General Hospital in July 2008 and had an active research laboratory focusing on melanoma tumorigenesis and immunotherapy for cancer. One exciting finding involved data describing the effect of BRAF-targeted therapy on tumor antigen expression in melanoma as a basis for combining targeted therapy and immunotherapy in the treatment of this disease. Dr. Wargo validated those findings in patients treated with BRAF inhibitors. She has continued critical studies to better understand the effects of BRAF inhibition on immune responses in melanoma, and established a unique set of serial tumor biopsies and blood samples from patients enrolled on clinical trials on BRAF inhibitors. Through analysis of these samples, she contributed significantly to the world literature regarding resistance mechanisms and the effect of targeted therapy on anti-tumor immunity. Dr. Wargo was recruited to MD Anderson Cancer Center in September 2013 to continue this work and to build a program to collect serial biopsies in patients with melanoma and other cancers on targeted therapy and immunotherapy, and to better understand responses to therapy and to develop novel strategies to combat resistance.
                          • Kevin Williams, PhD
                            Associate Professor, Biomanufacturing Research Institute and Technology Enterprise, NC Central University
                            Biography
                              Dr. Kevin P. Williams, Ph.D. is an Associate Professor in the Department of Pharmaceutical Sciences and a faculty member of BRITE at North Carolina Central University. Dr. Williams has over 25 years combined experience in both academic and biopharmaceutical-based research with a focus on cancer and drug discovery. Dr. Williams received his B.Sc. in Biochemistry from the University of Bath in the UK and received his Ph.D. in Biochemistry from the University of Cambridge (UK). He completed his postdoctoral work at Massachusetts General Hospital and the Joslin Diabetes Center in Boston. Prior to joining NCCU in 2007, he spent six years as a Senior Scientist at Biogen in the Department of Protein Engineering and four years at Amphora Corp as Director of Enzyme Drug Discovery. At NCCU he has obtained NIH and DOD research support and mentored 12 Masters level graduate students. His lab currently focuses on identifying novel modulators of the hedgehog pathway. Dr. Williams serves as course director and main instructor for the undergraduate bioprocessing and graduate-level biomanufacturing classes. He is co-author of over 45 publications and co-inventor on 9 patents.
                            • Lori Wirth, MD
                              Medical Director, Head and Neck Oncology, Massachusetts General Hospital
                              Biography
                                Dr. Lori Wirth is Medical Director of Massachusetts General Hospital's Center for Head and Neck Cancers and Associate Professor in Medicine at Harvard Medical School. Dr. Wirth received her BA from Brown University and MD from Columbia's College of Physicians and Surgeons. She trained at New York Presbyterian Hospital and Dana-Farber/Harvard Cancer Center. Dr. Wirth is an authority in advanced thyroid cancer and head and neck oncology, with expertise new therapies for head and neck and thyroid cancers. Her research focuses on clinical trials and leveraging translational data to maximize the impact of trial outcomes. In addition to overseeing the Center for Head and Neck Cancers, Dr. Wirth co-directs Mass General/Mass Eye and Ear's Advanced Thyroid Cancer Clinic. Dr. Wirth is Immediate Past Chairperson of the International Thyroid Oncology Group, and sits on a number of national and international oncology committees, including NCCN's Thyroid Committee and ABIM's Medical Oncology Exam Committee.
                              Sponsored By

                              For information on becoming a sponsor or exhibitor, please click here.


                              C.E. Credits

                              The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                              Committee

                              To download the Program Committee brochure here.


                              • David Albala, MD

                                Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr ...

                                See more See less
                              • Sharon Geaghan, MD

                                Dr. Geaghan is Chief, Pathology at Lucile Packard Children's Hospital at Stanford, and Co-Director of Clinical Laboratories at Stanford Hospital and Clinics. She also directs the Bass Pediatric Cancer Center Laboratory at the Lucile Packard Hospital; is Director of the Point of ...

                                See more See less
                              • Josip Blonder, MD

                                Dr. Blonder leads the Clinical Proteomics Group at the CRTP/FNL. FNL is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute (NCI). In 1978, Dr. Blonder received his M.D. at the Rijeka University ...

                                See more See less
                              • Peter Blume-Jensen, MD, PhD

                                Dr. Peter Blume-Jensen has extensive expertise in basic and translational cancer research, oncogenic signaling, and targeted oncology therapeutics drug discovery prior to joining Metamark as CSO in 2010.  From 2001 to 2008 Peter was department head at first Serono, US and ...

                                See more See less
                              • Fred Russell Kramer, PhD

                              • Martin Latterich, PhD

                                The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ...

                                See more See less
                              • Ariel Louwrier PhD

                                Successful Senior Scientific Business Executive with demonstrated expertise growing markets, revenues, product pipelines and expanding technical organizations into new business opportunities. Educational and business management experience in global markets, with quantified ...

                                See more See less
                              • Judd Moul, MD, FACS

                                Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of ...

                                See more See less
                              • Thomas Polascik, MD

                                Thomas J. Polascik, M.D. is Professor in the Duke Cancer Institute, the Department of Surgery at the Duke University Medical Center, Durham, NC. Dr. Polascik trained at the Brady Urological Institute, the Johns Hopkins Hospital in Baltimore Maryland. After finishing his residency ...

                                See more See less
                              • Rajan Gupta, MD

                                Dr. Rajan T. Gupta, MD, is an Assistant Professor of Radiology in the Division of Abdominal Imaging at Duke University Medical Center, as well as the Director of the Abdominal Imaging Fellowship Program and a Faculty physician in the Duke Cancer Institute. Since 2009, he has been ...

                                See more See less
                              • Antonio Baines, PhD

                                Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a ...

                                See more See less
                              • Louise Perkins, PhD

                                Dr. Perkins joined the Melanoma Research Alliance as Chief Science Officer in 2013 where she is responsible for the development and implementation of the MRA's scientific strategy including its research award program and annual Scientific Retreat. Her interests center on ...

                                See more See less
                              • Martin Latterich, PhD

                                The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ...

                                See more See less
                              Help

                              General LabRoots Questions

                              For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                              Contact us

                              Virtual Events and Webinars

                              Supported Configurations

                              • Operating System Internet Explorer Firefox Chrome Safari
                                Vista IE8+ FF10+ Chrome15+
                                Windows 7 IE8+ FF10+ Chrome15+
                                Windows 8 IE10 FF10+ Chrome15+
                                Mac OS X   FF10+ Chrome15+ Safari5.1+
                              • Cookie settings: session cookies enabled
                              • Browser configuration must have JavaScript enabled
                              • Adobe Flash player 10.2 or later

                              To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                              Internet Connection

                              • A minimum of 100Kbps is recommended for audio-only events
                              • A minimum of 300Kbps is recommended for speaker on-video events

                              Computer Equipment

                              • Screen Resolution: Minimum 1024x768
                              • Video Card: 65,000 colors minimum
                              • Sound card and speakers (or headphones) for hearing webcast in full format
                              • Audio Card: 16-bit minimum
                              • RAM: 512MB of free RAM

                              Firewall Protocol

                              • HTTP on port 80 or HTTPS on port 443
                              • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                              • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                              Work-At-Home Attendees

                              • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                              For A Seamless Experience

                              When using a mobile device, FREE Mobile Apps are available:

                              - For viewing Webinars:

                              - For viewing Virtual Events

                              Attendee Guide

                              • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                              Virtual Event and Webinar Support:

                              Continuing Education (CME/CE) Support

                              Loading Comments...